Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (Cmax) of at least about 0.25 μg/gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.Board of Regents, University of Texas Syste
Enhanced therapeutics are drug products derived from existing generic drugs that provide additional ...
During the past decade, pulmonary drug delivery (PDD) technology advanced substantially due to sever...
Significant advances have been made in the last 50 years in developing safe and efficacious aerosol ...
Inhalable compositions are described. The inhalable compositions comprise one or more respirable agg...
The present invention includes compositions and methods for making and using a rapid dissolving, hig...
Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or ...
Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or ...
The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and ...
The present invention includes compositions and methods for treating and delivering medicinal formul...
The pulmonary route of drug delivery can provide an excellent alternative to other routes both for l...
It is well established that currently available inhaled drug formulations are associated with extrem...
The present invention is drawn to methods of enhancing bioavailability, pulmonary absorption and/or ...
In respiratory drug delivery the lungs or the nose are exploited as absorption sites for the adminis...
The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and ...
Drug delivery to the lungs by inhalation offers a targeted drug therapy for respiratory diseases. Ho...
Enhanced therapeutics are drug products derived from existing generic drugs that provide additional ...
During the past decade, pulmonary drug delivery (PDD) technology advanced substantially due to sever...
Significant advances have been made in the last 50 years in developing safe and efficacious aerosol ...
Inhalable compositions are described. The inhalable compositions comprise one or more respirable agg...
The present invention includes compositions and methods for making and using a rapid dissolving, hig...
Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or ...
Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or ...
The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and ...
The present invention includes compositions and methods for treating and delivering medicinal formul...
The pulmonary route of drug delivery can provide an excellent alternative to other routes both for l...
It is well established that currently available inhaled drug formulations are associated with extrem...
The present invention is drawn to methods of enhancing bioavailability, pulmonary absorption and/or ...
In respiratory drug delivery the lungs or the nose are exploited as absorption sites for the adminis...
The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and ...
Drug delivery to the lungs by inhalation offers a targeted drug therapy for respiratory diseases. Ho...
Enhanced therapeutics are drug products derived from existing generic drugs that provide additional ...
During the past decade, pulmonary drug delivery (PDD) technology advanced substantially due to sever...
Significant advances have been made in the last 50 years in developing safe and efficacious aerosol ...